BRAF and colorectal carcinoma: One case, a CRC patient with mutant BRAF V600E, had PR to 2 cycles of treatment with the BRAF inhibitor, vemurafenib, and the anti-EGFR monoclonal antibody, cetuximab (HO20) (Figure 6A).